Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-07-04
2006-07-04
Carlson, Karen Cochrane (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200, C530S351000, C530S300000, C530S350000
Reexamination Certificate
active
07071160
ABSTRACT:
Using the proteins of the present invention, DNAs encoding the proteins, and antibodies recognizing the proteins, detection methods for diseases relating to the novel insulin-like growth factor binding proteins of the present invention, as well as diagnostic agents, preventive agents, and therapeutic agents for diseases relating to the proteins of the present invention can be provided.
REFERENCES:
patent: 2003/0148485 (2003-08-01), Taupier et al.
patent: WO 00/36105 (2000-06-01), None
patent: WO 01/83705 (2001-11-01), None
patent: WO 01/93983 (2001-12-01), None
Yamauchi, T., et al., “Purification and molecular cloning of prostacyclin-stimulating factor from serum-free conditioned medium of human diploid fibroblast cells” Biochem J., vol. 303 (Pt.2), pp. 591-598, (1994).
Murphy, M., et al., “Identification and characterization of genes differentially expressed in meningiomas”, Cell Growth & Differentiation, vol. 4 (9), pp. 715-722, (1993).
Swisshelm, K., et al., “Enhanced expression of an insulin growth factor-like binding protein (mac25) in senescent human mammary epithelial cells and induced expression with retinoic acid” Proc. Nat'l Acad. Sci. USA, vol. 92(10), pp. 4472-4476 (1995).
Hwa, Vivian et al.; “The Insulin-Like Growth Factor-Binding Protein (IGFBP) Superfamily”;Endocrine Reviews; 1999; pp. 761-787; vol. 20, No. 6; The Endocrine Society; U.S.A.
Murphy, L. J.; “Insulin-like growth factor-binding proteins: functional diversity or redundancy”;Journal of Molecular Endocrinology; 1998; pp. 97-107; vol. 21; Society for Endocrinology: Great Britain.
Perks, Claire M. and Jeff M. P. Holly, “Insulin-Like Growth Factor Binding Proteins (IGFBPs) in Breast Cancer”;Journal of Mammary Gland Biology and Neoplasia; 2000; pp. 75-84; vol. 5, No. 1; Plenum Publishing Corporation.
Schneider, Marlon R. et al.; “Transgenic mouse models for studying the functions of insulin-like growth factor-binding proteins”;FASEB J.; 2000; pp. 629-640; vol. 14; FASEB.
Wetterau, Lawrence A. et al.; “Novel Aspects of the Insulin-like Growth Factor Binding Proteins”;Molecular Genetics and Metabolism; 1999; pp. 161-181; vol. 68; Academic Press.
EMBL Accession No. BC007758; In: Strausberg, R. L. et al.; “Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences”;Proc. Natl. Acad. Sci. U.S.A.; 2002; pp. 16899-16903; vol. 99, No. 26.
EMBL Accession No. AX358831; In: WO 01/93983; Genentech, Inc., “Secreted and transmembrane polypeptides and nucleic acids encoding the same”; Dec. 13, 2001.
Furuya Akiko
Kobayashi Yuki
Nakamura Yusuke
Ota Toshio
Satoh Mitsuo
Carlson Karen Cochrane
Kyowa Hakko Kogyo Co. Ltd.
Townsend & Townsend and Crew LLP
LandOfFree
Insulin-like growth factor-binding protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Insulin-like growth factor-binding protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Insulin-like growth factor-binding protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3553547